News from January 2017
- Jan (24)
- Feb (27)
- Mar (15)
- Apr (23)
- May (34)
- Jun (28)
- Jul (26)
- Aug (11)
- Sep (19)
- Oct (20)
- Nov (28)
- Dec (14)
- Jan (14)
- Feb (22)
- Mar (21)
- Apr (12)
- May (20)
- Jun (23)
- Jul (20)
- Aug (5)
- Sep (19)
- Oct (19)
- Nov (26)
- Dec (15)
- Jan (4)
- Feb (18)
- Mar (13)
- Apr (15)
- May (19)
- Jun (22)
- Jul (18)
- Aug (9)
- Sep (11)
- Oct (25)
- Nov (19)
- Dec (15)
- Jan (12)
- Feb (6)
- Mar (13)
- Apr (5)
- May (7)
- Jun (15)
- Jul (11)
- Aug (3)
- Sep (5)
- Oct (8)
- Nov (15)
- Dec (13)
Scientists at Salk Institute have made breakthroughs in the integration of human cells into embryos of a different species
Scientists at Salk Institute for Biological Studies in California have made breakthroughs on multiple fronts in the race to integrate pluripotent ste1
Josep Dalmau, Chair of the new Autoimmune Neurology Section in the American Academy of Neurology
Dr. Josep Dalmau, ICREA Professor of IDIBAPS, where he leads the Group Pathogenesis of autoimmune neuronal disorders, and consultant of the Neurology1
A treatment increases survival by 50% in mice with Niemann-Pick type C, a rare disease that affects brain and liver
Researchers from the IIBB-CSIC and the IDIBAPS publish an article in the journal Redox Biology in which they propose an alternative treatment for Nie1
A diagnostic test for lung cancer detects genetic alterations which may remain hidden when conventional techniques are used
A study led by researchers from Hospital Clínic-IDIBAPS, in collaboration with Dexeus University Hospital, shows the effectiveness of a new genetic1
Researchers discover a protein that protects against fatty liver, the most common hepatic disease in Western countries
A team co-headed by scientists at the Institute for Research in Biomedicine (IRB Barcelona) and the IDIBAPS Biomedical Research Institute (part of t1
Hospital Clinic-IDIBAPS leads a European project to fight against cirrhosis within the Horizon 2020 program
Hospital Clínic-IDIBAPS is leading a European project to evaluate the efficacy of treatment with the combination of rifaximin, an antibiotic that mo1
Transplant Biomedical receives an economical injection to develop an organ preservation device
Transplant Biomedical, one of the two spin-offs arising from IDIBAPS, will receive a maximum of 2.5 million euros to carry out the clinical phase of1
A new drug has been developed for the treatment of autoimmune diseases
IDIBAPS researchers have participated in a study that shows how a new experimental drug could curb a wide variety of autoimmune diseases such as ast1